1
|
Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MAS, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep 2015; 10:755-770. [PMID: 25660025 PMCID: PMC4524791 DOI: 10.1016/j.celrep.2015.01.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Revised: 12/17/2014] [Accepted: 01/06/2015] [Indexed: 12/11/2022] Open
Abstract
Novel therapeutic approaches are urgently required for multiple myeloma (MM). We used a phenotypic screening approach using co-cultures of MM cells with bone marrow stromal cells to identify compounds that overcome stromal resistance. One such compound, BRD9876, displayed selectivity over normal hematopoietic progenitors and was discovered to be an unusual ATP non-competitive kinesin-5 (Eg5) inhibitor. A novel mutation caused resistance, suggesting a binding site distinct from known Eg5 inhibitors, and BRD9876 inhibited only microtubule-bound Eg5. Eg5 phosphorylation, which increases microtubule binding, uniquely enhanced BRD9876 activity. MM cells have greater phosphorylated Eg5 than hematopoietic cells, consistent with increased vulnerability specifically to BRD9876's mode of action. Thus, differences in Eg5-microtubule binding between malignant and normal blood cells may be exploited to treat multiple myeloma. Additional steps are required for further therapeutic development, but our results indicate that unbiased chemical biology approaches can identify therapeutic strategies unanticipated by prior knowledge of protein targets.
Collapse
Affiliation(s)
- Shrikanta Chattopadhyay
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
| | - Alison L Stewart
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Siddhartha Mukherjee
- Department of Medicine and Irving Cancer Research Center, Columbia University School of Medicine, New York, NY 10032, USA
| | - Cherrie Huang
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | - Peter G Miller
- Harvard Medical School, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | | | - Leigh C Carmody
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Rushdia Z Yusuf
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | - David B Sykes
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Joshiawa Paulk
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Harvard University, Cambridge, MA 02138, USA
| | - Amedeo Vetere
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Sonia Vallet
- Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Loredana Santo
- Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | | | - Vlado Dančík
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Max M Majireck
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Harvard University, Cambridge, MA 02138, USA
| | - Mahmud M Hussain
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Broad Institute, Cambridge, MA 02142, USA
| | - Shambhavi Singh
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Harvard University, Cambridge, MA 02138, USA
| | - Ryan Quiroz
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Jonathan Iaconelli
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Rakesh Karmacharya
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA; Schizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont, MA 02478, USA
| | - Nicola J Tolliday
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Paul A Clemons
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Malcolm A S Moore
- Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Andrew M Stern
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Alykhan F Shamji
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Benjamin L Ebert
- Dana-Farber Cancer Institute, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Todd R Golub
- Cancer Program, Broad Institute, Cambridge, MA 02142, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Howard Hughes Medical Institute, Broad Institute, Cambridge, MA 02142, USA
| | - Noopur S Raje
- Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | - David T Scadden
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Harvard University, Cambridge, MA 02138, USA
| | - Stuart L Schreiber
- Center for the Science of Therapeutics / Center for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Broad Institute, Cambridge, MA 02142, USA.
| |
Collapse
|
9
|
Matsuo Y, Drexler HG, Kaneda K, Kojima K, Ohtsuki Y, Hara M, Yasukawa M, Tanimoto M, Orita K. Megakaryoblastic leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with myeloid/NK precursor phenotype. Leuk Res 2003; 27:165-71. [PMID: 12526922 DOI: 10.1016/s0145-2126(02)00081-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The megakaryoblastic leukemia cell line MOLM-16 was established at relapse from the peripheral blood of a 77-year-old Japanese woman with minimally differentiated acute myeloid leukemia (AML-M0). Immunophenotyping of the fresh leukemic cells revealed a myeloid/NK precursor phenotype being positive for CD7, CD13, CD33, CD34, and CD56. In addition, megakaryocyte-associated antigens CD41 and CD61 were found to be positive. The established cell line designated MOLM-16 was proliferatively responsive to the treatment with various cytokines including EPO, GM-CSF, IL-3, PIXY-321, and TPO. MOLM-16 revealed characteristics of the megakaryocytic lineage in terms of immunophenotyping being positive for CD9, CD31, CD36, CD41, CD61, CD62P, CD63, CD110, CD151, thrombospondin, von Willebrand factor (vWf), and fibrinogen. Electron microscopic analysis showed positivity for ultrastructural platelet peroxidase in the nuclear envelope. The karyotype analysis of MOLM-16 revealed various numerical and structural abnormalities including t(6;8)(q21;q24.3), t(9;18)(q13;q21) and marker chromosomes. The extensive immunological, cytogenetic and functional characterization of MOLM-16 suggests that this cell line may represent a scientifically significant in vitro model which could facilitate the evaluation of megakaryocytic differentiation.
Collapse
MESH Headings
- Aged
- Cell Differentiation
- Cell Division/drug effects
- Cell Lineage
- Chromosomes, Human, Pair 18
- Chromosomes, Human, Pair 6
- Chromosomes, Human, Pair 8
- Chromosomes, Human, Pair 9
- Cytogenetic Analysis
- Cytokines/pharmacology
- Female
- Humans
- Immunophenotyping
- Killer Cells, Natural/immunology
- Killer Cells, Natural/pathology
- Leukemia, Megakaryoblastic, Acute/genetics
- Leukemia, Megakaryoblastic, Acute/pathology
- Microscopy, Electron, Scanning
- Myeloid Cells/immunology
- Myeloid Cells/pathology
- Recurrence
- Translocation, Genetic
- Tumor Cells, Cultured/cytology
Collapse
Affiliation(s)
- Yoshinobu Matsuo
- Fujisaki Cell Center, Hayashibara Biochemical Labs Inc., Fujisaki, Okayama 702-8006, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|